Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Effectiveness of XCell on Autolytic Debridement of Venous Ulcers

NCT00446823 · View on ClinicalTrials.gov ↗

Study Summary

This clinical trial is designed to evaluate the effect of XCell cellulose wound dressing for its ability to naturally (autolytically) remove nonviable tissue and create a healthy vascular wound bed. Results will compare venous ulcers treated with Xylos XCell cellulose dressing plus standard care to those treated with standard care alone. The hypothesis is that XCell will demonstrate more autolytic debridement than the standard of care.

Conditions Studied

Interventions

  • DEVICE XCell cellulose wound dressing
  • DEVICE Impregnated gauze dressing

Study Locations (3)

Massachusetts

  • Boston University School of Medicine — Boston

New York

  • University Wound Care Center — The Bronx

Pennsylvania

  • Etris Associates — Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2002-06
Est. Completion 2003-12
Phase NA

Sponsor

Xylos Corporation

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00446823

The ClinicalTrials.gov registry entry for NCT00446823 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xylos Corporation, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Venous Ulcer appearing as the primary indexed condition, and to 2 interventions — of which XCell cellulose wound dressing is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00446823 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Massachusetts, New York, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00446823 about?

NCT00446823 is a clinical study titled "Effectiveness of XCell on Autolytic Debridement of Venous Ulcers". This clinical trial is designed to evaluate the effect of XCell cellulose wound dressing for its ability to naturally (autolytically) remove nonviable tissue and create a healthy vascular wound bed. Results will compare venous ulcers treated with Xylos XCell cellulose dressing plus standard care to ...

What is the current status of trial NCT00446823?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2002-06. Estimated completion is 2003-12.

What conditions does trial NCT00446823 study?

This clinical trial studies the following conditions: Venous Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00446823?

The interventions under investigation include: XCell cellulose wound dressing (DEVICE), Impregnated gauze dressing (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00446823?

This trial is sponsored by Xylos Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00446823 being conducted?

This trial has 3 study locations across Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial